Ibex Technologies (TSXV:IBT) Total Current Assets : C$10.50 Mil (As of Jan. 2024)

View and export this data going back to 1986. Start your Free Trial

What is Ibex Technologies Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Ibex Technologies's total current assets for the quarter that ended in Jan. 2024 was C$10.50 Mil.

Ibex Technologies Total Current Assets Historical Data

The historical data trend for Ibex Technologies's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ibex Technologies Total Current Assets Chart

Ibex Technologies Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Total Current Assets

Get a 7-Day Free Trial

3.71

4.92

5.83

9.03

10.23

Ibex Technologies Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Total Current Assets	Get a 7-Day Free Trial															8.83	9.76	10.23	11.04	10.50

Ibex Technologies Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Ibex Technologies's Total Current Assets for the fiscal year that ended in Jul. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	8.547	+	1.343	+	0.171	+	0.167
	=	10.23

Ibex Technologies's Total Current Assets for the quarter that ended in Jan. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	8.692	+	1.468	+	0.254	+	0.09
	=	10.50

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Ibex Technologies (TSXV:IBT) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Ibex Technologies's Liquidation Value for the quarter that ended in Jan. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8.692	-	2.997	+	0.75 * 1.062	+	0.5 * 0.254
=	6.62

Ibex Technologies Total Current Assets Related Terms

Thank you for viewing the detailed overview of Ibex Technologies's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Ibex Technologies (TSXV:IBT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ibex Technologies Inc (TSXV:IBT) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

IBXNF:USA IBT:Germany

Address

5485 Pare Street, Suite 100, Montreal, QC, CAN, H4P 1P7

Website

https://www.ibex.ca

Ibex Technologies Inc is a company engaged in the production and sale of diagnostic products. It manufactures and markets enzymes for biomedical use, through its subsidiaries. It also manufactures and markets a series of arthritis assays that have applications in osteoarthritis research. It sells two product lines namely, Enzymes for in-vitro diagnostics and research, and Tests for osteoarthritis research. The group provides services like Filing and lyophilization of disposable diagnostic components, and Custom fermentation and purification of enzymes for diagnostic companies. Geographically, the firm sells its products in Canada, Germany, the U.S., the U.K., and other countries of which the majority of the revenue is generated from the U.S.

Ibex Technologies (TSXV:IBT) Headlines

No Headlines